Insider Traders Outside U.S. Safe From American Prisons
This article is for subscribers only.
InterMune Inc. had good news to announce about its lung disease drug.
On Dec. 17, 2010, the California biotechnology firm said European Union regulators had recommended approval of the medicine for sale in Europe. Its shares rose 144 percent, while some options to buy the stock gained more than 500 percent.